Hip fracture patients are not treated for osteoporosis: A call to action

Objective To determine whether hip fracture patients, a group at very high risk for additional fragility fractures, are being evaluated and treated effectively for osteoporosis. Methods Clinical and bone densitometry (dual x‐ray absorptiometry [DXA]) records were reviewed in hip fracture patients at...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis and rheumatism 2002-12, Vol.47 (6), p.651-654
Main Authors: Harrington, J. Timothy, Broy, Susan B., Derosa, Angela M., Licata, Angelo A., Shewmon, David A.
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Alendronate - therapeutic use
Biological and medical sciences
Calcitonin - therapeutic use
Calcium - therapeutic use
Diseases of the osteoarticular system
Estrogen Antagonists - therapeutic use
Estrogens - therapeutic use
Hip fracture
Hip Fractures - epidemiology
Hip Fractures - etiology
Hip Fractures - prevention & control
Humans
Injuries of the limb. Injuries of the spine
Medical sciences
Osteoporosis
Osteoporosis - complications
Osteoporosis - drug therapy
Osteoporosis - epidemiology
Osteoporosis. Osteomalacia. Paget disease
Raloxifene Hydrochloride - therapeutic use
Retrospective Studies
Risk Factors
Traumas. Diseases due to physical agents
Treatment Failure
Vitamin D - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To determine whether hip fracture patients, a group at very high risk for additional fragility fractures, are being evaluated and treated effectively for osteoporosis. Methods Clinical and bone densitometry (dual x‐ray absorptiometry [DXA]) records were reviewed in hip fracture patients at 4 Midwestern US health systems to determine the frequency of DXA use, calcium and vitamin D supplementation, and antiresorptive drug treatment. Results DXA was performed at the 4 study sites in only 12%, 12%, 13%, and 24% of patients, respectively. Calcium and vitamin D supplements were prescribed in 27%, 1%, 3%, and 25% of the patients at the 4 study sites. Antiresorptive drugs were prescribed in 26%, 12%, 7%, and 37% of the patients with only 2–10% receiving a bisphosphonate. Conclusion Reducing osteoporotic fractures will require more effective approaches to managing hip fracture patients and other high‐risk populations.
ISSN:0004-3591
0893-7524
1529-0131
1529-0123
DOI:10.1002/art.10787